Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial

Among 35,572 patients, semaglutide was associated with a lower risk of major adverse cardiovascular events compared to dulaglutide.

• Semaglutide was linked to a risk reduction in major adverse cardiovascular events (MACE) with a hazard ratio of 0.85.
• Expanded MACE, which includes hospitalization for heart failure and revascularization, showed a similar risk reduction for semaglutide (HR 0.92).
• All-cause mortality risk was lower for patients taking semaglutide (HR 0.81) compared to those on dulaglutide.
• Patients on semaglutide experienced a reduced risk of stroke (HR 0.82) and revascularization (HR 0.93).
• Liraglutide also demonstrated a lower risk of MACE (HR 0.84) and all-cause mortality (HR 0.79) compared to dulaglutide.

AI simplified